ARTICLE | Finance
In BioCentury’s Venture Report: Fundings for Citryll, Angitia, Tasca, Veradermics and more
By BioCentury Staff
December 13, 2024 1:25 AM UTC
Not every venture firm is going bigger with its latest fund, but techbio investor Dimension Capital has closed its latest fund at $500 million — 43% larger than its Dimension I fund, announced in early 2023. The digital biology-focused firm aims to bridge computer science and life sciences, investing in start-ups that use AI and other computational technologies to create therapeutics.
Among its investments thus far are Enveda Therapeutics Inc., whose potentially first-in-class therapy for atopic dermatitis has entered the clinic and could represent a pipeline-in-a-product opportunity; Monte Rosa Therapeutics Inc. (NASDAQ:GLUE), which has therapeutics for cancer and autoimmune diseases in human testing; and Carmot Therapeutics Inc. spinout Kimia Therapeutics Inc., seeking to build a chemical atlas that can guide therapeutic design…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654459/techbio-vc-dimension-upsizes-for-500m-second-fund-pe-firm-takes-stake-in-andera